Working on neglected diseases in Chile
In a column written by Dr. Luis Pizarro and Pedro Bouchon they explain the urgency for countries like ours to tackle Neglected Diseases and the advantage for local universities to research them.
photo_camera (César Cortés)
Believe it or not, in the modern world, many diseases still do not receive enough investment for research and development, and treatments remain old, ineffective, toxic, or simply non-existent.
Usually, they affect the world’s most vulnerable populations.
For instance, Chagas disease, hantavirus, and hepatitis C in Chile are still not sufficiently researched.
Thanks to the Drugs for Neglected Diseases initiative (DNDi), it has been possible to develop 12 affordable, available, and community-adapted treatments for six deadly diseases, such as Hepatitis C.
In a column written for the Chilean newspaper La Tercera, Dr. Luis Pizarro and Pedro Bouchon explain:
- the urgency for countries like ours to tackle these diseases
- and the advantage for local universities to research them.
Read the complete column written by Dr. Luis Pizarro, Executive Director of the Drugs for Neglected Diseases initiative (DNDi), and Pedro Bouchon, Vice President for Research at the Pontificia Universidad Católica de Chile (UC Chile).
